Three months after its shares were clobbered on disappointing survival data in non-small-cell lung cancer (NSCLC), ArQule Inc.'s stock sank again, after tivantinib, its MET inhibitor, missed primary and secondary endpoints in a Phase II trial in second-line colorectal cancer (CRC).